Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Amgen Says FDA Approves Kyprolis Combination to Treat Multiple Myeloma

12/01/2021 | 02:12pm EST

By Stephen Nakrosis

Amgen Inc. said Wednesday the U.S. Food and Drug Administration approved Kyprolis in a combination regime to treat certain adult patients with relapsed or refractory multiple myeloma.

The company said the FDA expanded Kyprolis' prescribing information to include its use with Darzalex Faspro, or daratumumab and hyaluronidase-fihj, and dexamethasone to treat adults with relapsed or refractory multiple myeloma who have received one to three lines of therapy.

Amgen said the expansion was supported by an ongoing Phase 2 trial evaluating Darzalex Faspro in combination with four standard-of-care treatment regimens in patients with multiple myeloma.

At 1:50 p.m. ET, Amgen shares were trading 2.4% higher at $203.59.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

12-01-21 1412ET

All news about AMGEN INC.
01/21Amgen - LUMAKRAS (SOTORASIB) RECEIVES APPROVAL IN JAPAN FOR PATIENTS WITH KRAS G12C-MUT..
AQ
01/20AMGEN PLUGS IN : Electric Vehicle Pilot Program Advances Carbon Neutrality Goal
PU
01/20Amgen Secures Japanese Approval of Non-Small Cell Lung Cancer Drug Lumakras
MT
01/20Amgen Inc.'s LUMAKRAS Receives Approval in Japan for Patients with KRAS G12C-Mutated Ad..
CI
01/20"SHOW MORE OF YOU" : Amgen V. Sandoz, Battling It Out On Amgen's Otezla« Drug
AQ
01/19FDA Clears CytomX's Investigational New Drug Application for CX-904 in Advanced Solid T..
MT
01/18Medicenna Therapeutics up 12.7% in US Trade, Details Management Change, Appoints Develo..
MT
01/14AMGEN : Teneobio Acquisition Adds Talent and New Types of Antibodies to Amgen
PU
01/13BridgeBio to Study BBP-398 With Amgen's Lumakras in Solid Tumors
DJ
01/13BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tu..
MT
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2021 26 017 M - -
Net income 2021 5 570 M - -
Net Debt 2021 21 988 M - -
P/E ratio 2021 21,9x
Yield 2021 3,13%
Capitalization 125 B 125 B -
EV / Sales 2021 5,66x
EV / Sales 2022 5,34x
Nbr of Employees 24 300
Free-Float -
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Last Close Price 222,54 $
Average target price 240,41 $
Spread / Average Target 8,03%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.-1.08%125 349
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642